Cargando…
Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes
Given vaccine dose shortages and logistical challenges, various deployment strategies are being proposed to increase population immunity levels to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Two critical issues arise: How timing of delivery of the second dose will affect infection...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128287/ https://www.ncbi.nlm.nih.gov/pubmed/33688062 http://dx.doi.org/10.1126/science.abg8663 |
_version_ | 1783694092415270912 |
---|---|
author | Saad-Roy, Chadi M. Morris, Sinead E. Metcalf, C. Jessica E. Mina, Michael J. Baker, Rachel E. Farrar, Jeremy Holmes, Edward C. Pybus, Oliver G. Graham, Andrea L. Levin, Simon A. Grenfell, Bryan T. Wagner, Caroline E. |
author_facet | Saad-Roy, Chadi M. Morris, Sinead E. Metcalf, C. Jessica E. Mina, Michael J. Baker, Rachel E. Farrar, Jeremy Holmes, Edward C. Pybus, Oliver G. Graham, Andrea L. Levin, Simon A. Grenfell, Bryan T. Wagner, Caroline E. |
author_sort | Saad-Roy, Chadi M. |
collection | PubMed |
description | Given vaccine dose shortages and logistical challenges, various deployment strategies are being proposed to increase population immunity levels to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Two critical issues arise: How timing of delivery of the second dose will affect infection dynamics and how it will affect prospects for the evolution of viral immune escape via a buildup of partially immune individuals. Both hinge on the robustness of the immune response elicited by a single dose as compared with natural and two-dose immunity. Building on an existing immuno-epidemiological model, we find that in the short term, focusing on one dose generally decreases infections, but that longer-term outcomes depend on this relative immune robustness. We then explore three scenarios of selection and find that a one-dose policy may increase the potential for antigenic evolution under certain conditions of partial population immunity. We highlight the critical need to test viral loads and quantify immune responses after one vaccine dose and to ramp up vaccination efforts globally. |
format | Online Article Text |
id | pubmed-8128287 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Association for the Advancement of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-81282872021-05-18 Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes Saad-Roy, Chadi M. Morris, Sinead E. Metcalf, C. Jessica E. Mina, Michael J. Baker, Rachel E. Farrar, Jeremy Holmes, Edward C. Pybus, Oliver G. Graham, Andrea L. Levin, Simon A. Grenfell, Bryan T. Wagner, Caroline E. Science Research Articles Given vaccine dose shortages and logistical challenges, various deployment strategies are being proposed to increase population immunity levels to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Two critical issues arise: How timing of delivery of the second dose will affect infection dynamics and how it will affect prospects for the evolution of viral immune escape via a buildup of partially immune individuals. Both hinge on the robustness of the immune response elicited by a single dose as compared with natural and two-dose immunity. Building on an existing immuno-epidemiological model, we find that in the short term, focusing on one dose generally decreases infections, but that longer-term outcomes depend on this relative immune robustness. We then explore three scenarios of selection and find that a one-dose policy may increase the potential for antigenic evolution under certain conditions of partial population immunity. We highlight the critical need to test viral loads and quantify immune responses after one vaccine dose and to ramp up vaccination efforts globally. American Association for the Advancement of Science 2021-04-23 2021-03-09 /pmc/articles/PMC8128287/ /pubmed/33688062 http://dx.doi.org/10.1126/science.abg8663 Text en Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution license (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Saad-Roy, Chadi M. Morris, Sinead E. Metcalf, C. Jessica E. Mina, Michael J. Baker, Rachel E. Farrar, Jeremy Holmes, Edward C. Pybus, Oliver G. Graham, Andrea L. Levin, Simon A. Grenfell, Bryan T. Wagner, Caroline E. Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes |
title | Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes |
title_full | Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes |
title_fullStr | Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes |
title_full_unstemmed | Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes |
title_short | Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes |
title_sort | epidemiological and evolutionary considerations of sars-cov-2 vaccine dosing regimes |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128287/ https://www.ncbi.nlm.nih.gov/pubmed/33688062 http://dx.doi.org/10.1126/science.abg8663 |
work_keys_str_mv | AT saadroychadim epidemiologicalandevolutionaryconsiderationsofsarscov2vaccinedosingregimes AT morrissineade epidemiologicalandevolutionaryconsiderationsofsarscov2vaccinedosingregimes AT metcalfcjessicae epidemiologicalandevolutionaryconsiderationsofsarscov2vaccinedosingregimes AT minamichaelj epidemiologicalandevolutionaryconsiderationsofsarscov2vaccinedosingregimes AT bakerrachele epidemiologicalandevolutionaryconsiderationsofsarscov2vaccinedosingregimes AT farrarjeremy epidemiologicalandevolutionaryconsiderationsofsarscov2vaccinedosingregimes AT holmesedwardc epidemiologicalandevolutionaryconsiderationsofsarscov2vaccinedosingregimes AT pybusoliverg epidemiologicalandevolutionaryconsiderationsofsarscov2vaccinedosingregimes AT grahamandreal epidemiologicalandevolutionaryconsiderationsofsarscov2vaccinedosingregimes AT levinsimona epidemiologicalandevolutionaryconsiderationsofsarscov2vaccinedosingregimes AT grenfellbryant epidemiologicalandevolutionaryconsiderationsofsarscov2vaccinedosingregimes AT wagnercarolinee epidemiologicalandevolutionaryconsiderationsofsarscov2vaccinedosingregimes |